Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality
- PMID: 20048215
- PMCID: PMC2824259
- DOI: 10.1161/CIRCULATIONAHA.108.838656
Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality
Abstract
Background: The Model for End-Stage Liver Disease (MELD) predicts events in cirrhotic subjects undergoing major surgery and may offer similar prognostication in left ventricular assist device candidates with comparable degrees of multisystem dysfunction.
Methods and results: Preoperative MELD scores were calculated for subjects enrolled in the University of Michigan Health System (UMHS) mechanical circulatory support database. Univariate and multiple regression analyses were performed to investigate the ability of patient characteristics, laboratory data (including MELD scores), and hemodynamic measurements to predict total perioperative blood product exposure and operative mortality. The ability of preoperative MELD scores to predict operative mortality was evaluated in subjects enrolled in the Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS), and results were compared with those from the UMHS cohort. The mean+/-SD MELD scores for the UMHS (n=211) and INTERMACS (n=324) cohorts were 13.7+/-6.1 and 15.2+/-5.8, respectively, with 29 (14%) and 19 (6%) perioperative deaths. In the UMHS cohort, median total perioperative blood product exposure was 74 units (25th and 75th percentiles, 44 and 120 units). Each 5-unit MELD score increase was associated with 15.1+/-3.8 units (beta+/-SE) of total perioperative blood product exposure. Each 10-unit increase in total perioperative blood product exposure increased the odds of operative death (odds ratio, 1.05; 95% confidence interval, 1.01 to 1.10). Odds ratios, measuring the ability of MELD scores to predict perioperative mortality, were 1.5 (95% confidence interval, 1.1 to 2.0) and 1.5 (95% confidence interval, 1.1 to 2.1) per 5 MELD units for the UMHS and INTERMACS cohorts, respectively. When MELD scores were dichotomized as >or=17 and <17, risk-adjusted Cox proportional-hazard ratios for 6-month mortality were 2.5 (95% confidence interval, 1.2 to 5.3) and 2.5 (95% confidence interval, 1.1 to 5.4) for the UMHS and INTERMACS cohorts, respectively.
Conclusions: The MELD score identified left ventricular assist device candidates at high risk for perioperative bleeding and mortality.
Figures
Similar articles
-
Model for end-stage liver disease score predicts adverse events related to ventricular assist device therapy.Ann Thorac Surg. 2012 May;93(5):1541-7; discussion 1547-8. doi: 10.1016/j.athoracsur.2012.02.008. Epub 2012 Apr 4. Ann Thorac Surg. 2012. PMID: 22480391
-
Predictive value of the model for end-stage liver disease score in patients undergoing left ventricular assist device implantation.ASAIO J. 2013 Jan-Feb;59(1):57-62. doi: 10.1097/MAT.0b013e31827c0c77. ASAIO J. 2013. PMID: 23263341
-
Pulmonary Arterial Elastance and INTERMACS-Defined Right Heart Failure Following Left Ventricular Assist Device.Circ Heart Fail. 2019 Aug;12(8):e005923. doi: 10.1161/CIRCHEARTFAILURE.119.005923. Epub 2019 Aug 12. Circ Heart Fail. 2019. PMID: 31401840
-
Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) Scoring System to Predict Outcomes in Patients Who Undergo Left Ventricular Assist Device Implantation.Ann Thorac Surg. 2018 Aug;106(2):513-519. doi: 10.1016/j.athoracsur.2018.02.082. Epub 2018 Apr 4. Ann Thorac Surg. 2018. PMID: 29626453
-
Preoperative liver dysfunction influences blood product administration and alterations in circulating haemostatic markers following ventricular assist device implantation.Eur J Cardiothorac Surg. 2015 Mar;47(3):497-504. doi: 10.1093/ejcts/ezu183. Epub 2014 May 7. Eur J Cardiothorac Surg. 2015. PMID: 24810756 Free PMC article.
Cited by
-
Combination of liver biopsy with MELD-XI scores for post-transplant outcome prediction in patients with advanced heart failure and suspected liver dysfunction.J Heart Lung Transplant. 2015 Jul;34(7):873-82. doi: 10.1016/j.healun.2014.12.009. Epub 2014 Dec 23. J Heart Lung Transplant. 2015. PMID: 25851466 Free PMC article.
-
To ventricular assist devices or not: When is implantation of a ventricular assist device appropriate in advanced ambulatory heart failure?World J Cardiol. 2016 Dec 26;8(12):695-702. doi: 10.4330/wjc.v8.i12.695. World J Cardiol. 2016. PMID: 28070237 Free PMC article.
-
Targeting Frailty in Heart Failure.Curr Treat Options Cardiovasc Med. 2017 Apr;19(4):31. doi: 10.1007/s11936-017-0527-5. Curr Treat Options Cardiovasc Med. 2017. PMID: 28357683 Review.
-
Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction.J Am Coll Cardiol. 2013 Jun 4;61(22):2253-2261. doi: 10.1016/j.jacc.2012.12.056. Epub 2013 Apr 3. J Am Coll Cardiol. 2013. PMID: 23563127 Free PMC article.
-
Prognostic value of vasoactive-inotropic score following continuous flow left ventricular assist device implantation.J Heart Lung Transplant. 2019 Sep;38(9):930-938. doi: 10.1016/j.healun.2019.05.007. Epub 2019 May 24. J Heart Lung Transplant. 2019. PMID: 31201088 Free PMC article.
References
-
- Goldstein DJ, Beauford RB. Left ventricular assist devices and bleeding: adding insult to injury. Annals of Thoracic Surgery. 2003;75:S42–7. - PubMed
-
- Pavie A, Szefner J, Leger P, Gandjbakhch I. Preventing, minimizing, and managing postoperative bleeding. Annals of Thoracic Surgery. 1999;68:705–10. - PubMed
-
- Murphy PJ, Connery C, Hicks GL, Jr, Blumberg N. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. Journal of Thoracic & Cardiovascular Surgery. 1992;104:1092–9. - PubMed
-
- Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL, McCarthy PM. Factors influencing HLA sensitization in implantable LVAD recipients. Annals of Thoracic Surgery. 1997;64:1120–5. - PubMed
-
- Moazami N, Itescu S, Williams MR, Argenziano M, Weinberg A, Oz MC. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. Journal of Heart & Lung Transplantation. 1998;17:876–80. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical